全部文献期刊学位论文会议报纸专利标准年鉴图书|学者科研项目
中外文文献  中文文献  外文文献
作者:Luc Dirix , Helen Swaisland ...
来源:[J].Clinical Therapeutics(IF 2.23), 2016, Vol.38 (10), pp.2286-2299Elsevier
摘要:Abstract(#br)Purpose(#br)The metabolism of olaparib, a potent inhibitor of poly(ADP-ribose) polymerase (PARP) with demonstrated efficacy in patients with BRCA -mutated ovarian cancer, is mediated by cytochrome P450 (CYP) enzymes (predominantly CYP3A4/5). We assessed the pote...
作者:Luc Dirix , Jeannie Hou ...
来源:[J].Journal of the American Academy of Dermatology(IF 4.906), 2015, Vol.72 (6), pp.1021-1026.e8Elsevier
摘要:Background(#br)Primary analysis from the pivotal ERIVANCE BCC study resulted in approval of vismodegib, a Hedgehog pathway inhibitor indicated for treatment of adults with metastatic or locally advanced basal cell carcinoma (BCC) that has recurred after surgery or for patients wh...
作者:Luc Dirix , Karl D. Lewis ...
来源:[J].Journal of the American Academy of Dermatology(IF 4.906), 2016, Vol.75 (1), pp.113-125.e5Elsevier
摘要:Background(#br)The hedgehog pathway inhibitor sonidegib demonstrated meaningful tumor shrinkage in more than 90% of patients with locally advanced basal cell carcinoma (BCC) or metastatic BCC in the BCC Outcomes with LDE225 Treatment study.(#br)Objective(#br)This report provides ...
作者:Luc Dirix , Henrik Grönberg
来源:[J].European Urology(IF 10.476), 2017Elsevier
摘要:Abstract(#br)Background(#br)Expression of the androgen receptor splice variant 7 (AR-V7) is associated with poor response to second-line endocrine therapy in castration-resistant prostate cancer (CRPC). However, a large fraction of nonresponding patients are AR-V7–negative.(...
作者:Luc Dirix , Walter Jonat ...
来源:[J].Breast Cancer Research and Treatment(IF 4.469), 2012, Vol.134 (3), pp.1149-1159Springer
摘要:Abstract(#br)Afatinib (BIBW 2992) is an ErbB-family blocker that irreversibly inhibits signaling from all relevant ErbB-family dimers. Afatinib has demonstrated preclinical activity in human epidermal growth factor receptor HER2 (ErbB2)-positive and triple-negative xenograft...
作者:Luc Dirix , Fred C. Sweep ...
来源:[J].Breast Cancer Research and Treatment(IF 4.469), 2013, Vol.139 (1), pp.39-49Springer
摘要:Abstract(#br) PIK3CA mutations occur frequently in breast cancer, predominantly in exons 9 and 20. The aim of this retrospective study is to evaluate the PIK3CA mutation status for its relationship with prognosis and first-line endocrine therapy outcome. PIK3CA exon 9 and 20...
作者:Luc Dirix , Patrice Viens ...
来源:[J].Breast Cancer Research and Treatment(IF 4.469), 2013, Vol.138 (3), pp.761-772Springer
摘要:Abstract(#br)Inflammatory breast cancer (IBC) is a unique clinical entity characterized by rapid onset of erythema and swelling of the breast often without an obvious breast mass. Many studies have examined and compared gene expression between IBC and non-IBC (nIBC), repeatedly f...
作者:Luc Dirix , Manon Huizing ...
来源:[J].Investigational New Drugs(IF 3.498), 2018, Vol.36 (3), pp.476-486Springer
摘要:Summary(#br) Purpose Trabectedin is metabolized by the liver and has been associated with transient, noncumulative transaminase elevation. Two recent studies further characterize hepatic tolerability with trabectedin therapy: a phase 1 pharmacokinetic study (Study #1004; NCT...
作者:Luc Dirix , Peter Grundtvig-Sørensen ...
来源:[J].Clinical Pharmacokinetics(IF 6.109), 2019, Vol.58 (9), pp.1165-1174Springer
摘要:Abstract(#br) Background(#br)Olaparib, a potent oral poly(ADP-ribose) polymerase inhibitor, is partially renally cleared. We investigated the pharmacokinetics and safety of olaparib in patients with mild or moderate renal impairment to provide dosing recommendations.(#br) Me...
作者:Luc Dirix , Jean-Christophe Thery ...
来源:[J].European Journal of Cancer(IF 5.061), 2016, Vol.53, pp.144-154Elsevier
摘要:Abstract(#br)Background(#br)Preclinical data suggest that epidermal growth factor receptor (EGFR) inhibitors (e.g. gefitinib) can delay endocrine resistance in breast cancer. A double-blind, placebo-controlled, phase II trial investigated whether adding gefitinib (G) to anastrozo...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×